Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceralasertib Alone or With Olaparib/Durvalumab in Solid Tumors
NCT03682289Phase 2Active, not recruiting
- Sponsor
- Rahul Aggarwal
- Start
- Jan 2019
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ceralasertib in renal cell carcinoma (RCC), urothelial carcinoma (UC), pancreatic cancer (PC), endometrial cancer (EC), prostate cancer (PCa), sponsored by Rahul Aggarwal. Started Jan 2019; status: active, not recruiting.
02
Drugs
ceralasertib
03
Conditions
renal cell carcinoma (RCC)urothelial carcinoma (UC)pancreatic cancer (PC)endometrial cancer (EC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03682289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03682289.